Washington Administrative Code

(1) The commission, under RCW 69.41.075, identifies ephedrine, or any of its salts in a solid or aqueous form normally intended for oral administration, in any quantity, as a legend drug subject to the restrictions of RCW 69.41.030.(2) The following products containing ephedrine …

(1) All legend drugs shall be dispensed in a child-resistant container as required by federal law or regulation, including 16 C.F.R., Part 1700, unless:(a) Authorization is received from the prescriber to dispense in a container that is not child-resistant.(b) Authorization is ob…

Except as provided in 21 C.F.R. 206.1 et seq., no nonimprinted solid dosage form drug that is intended for OTC sale may be distributed into or sold in the state of Washington unless it has been found by the commission to be exempt from the provisions of this chapter or has receiv…

(1) The commission identifies the following as an over-the-counter drug in Washington:(a) 4 mg naloxone hydrochloride nasal spray, approved by the FDA for marketing as an OTC drug product.(b) 3 mg naloxone hydrochloride nasal spray, approved by the FDA for marketing as an OTC dru…

(1) Except as provided in subsection (2) of this section, a pharmacy shall not possess, distribute or dispense legend drug samples.(2) A pharmacy of a licensed hospital or health care entity which receives and distributes drug samples at the request of an authorized practitioner …

The following drugs are classified as steroids for the purposes of RCW 69.41.310. The drugs designated shall include the following and any synthetic derivatives or any isomer, ester, salt, or derivative of the following that act in the same manner on the human body:(1) Anabolicum…

(1) Amygdalin (laetrile) may be manufactured and distributed through intrastate commerce in Washington in accordance with all applicable state laws and regulations.(2) Amygdalin (laetrile) imported into the state of Washington shall be imported in conformity with federal regulati…

(1) The commission adopts and incorporates Title 21 of the Code of Federal Regulations in effect as of March 2, 2023, by reference. The following sections of 21 C.F.R. do not apply: Sec. 6.1 - 6.5, Sec. 58.1 - 58.15, Sec. 83 - 98, Sec. 100 - 199, Sec. 225 - 226, Sec. 291, Sec. 37…

The commission hereby designates, the following Schedule II controlled substances as nonnarcotic stimulants for purposes of RCW 69.50.402 (1)(c):(1) Amphetamine sulfate in any of its generic forms.(2) Dextroamphetamine sulfate in any of its generic forms and under the following b…

The Schedule II stimulants listed in WAC 246-945-043 may be prescribed, dispensed, or administered to patients for the following disease states or conditions:(1) Disease states or conditions listed in RCW 69.50.402 (1)(c)(ii); and(2) Moderate to severe binge eating disorder in ad…

In addition to any criminal or civil liabilities that may occur, the commission may deny, suspend, or revoke registration upon determination that:(1) The registration was procured through fraud or misrepresentation;(2) The registrant or any agent or employee of the registrant has…

Pursuant to the authority granted to the commission in RCW 69.50.201, the commission has considered the following factors with regards to each of the substances listed in this chapter and in chapter 69.50 RCW:(1) The actual or relative potential for abuse;(2) The scientific evide…

The commission, under RCW 69.50.201, deletes the following substance listed in RCW 69.50.210 from Schedule IV in the state of Washington.Fenfluramine. Any material, compound, mixture, or preparation containing any quantity of the following substance, including its salts, isomers,…

The commission finds that the following substances have high potential for abuse and have no accepted medical use in treatment in the United States or that they lack accepted safety for use in treatment under medical supervision. In addition to the substances scheduled in RCW 69.…

The commission finds that the following substances have a high potential for abuse and have currently accepted medical use in treatment in the United States, or currently accepted medical use with severe restrictions and that the abuse of the following substances may lead to seve…

The commission finds and designates the following substances as being the principal compound used or produced primarily for use and which are an immediate chemical intermediary used or likely to be used, in the manufacture of a Schedule II controlled substance, the control of whi…

The commission finds that the following substances have a potential for abuse less than the substances listed in Schedule I under RCW 69.50.204 and WAC 246-945-051 and Schedule II under RCW 69.50.206 and WAC 246-945-052, and have currently accepted medical use in treatment in the…

The commission finds that the following substances have a low potential for abuse relative to substances in Schedule III under RCW 69.50.208 and WAC 246-945-054, and have currently accepted medical use in treatment in the United States and that the abuse of the substances may lea…

The commission finds that the following substances have low potential for abuse relative to substances in Schedule IV under RCW 69.50.210 and WAC 246-945-055 and have currently accepted medical use in treatment in the United States and that the substances have limited physical de…

(1) All persons and firms, except persons exempt from registration, must register with the commission in order to legally possess or use controlled substances.(2) Persons or firms which are not classified as pharmacies, wholesalers, manufacturers, or researchers will be classifie…

The definitions in this section apply to WAC 246-945-065 through 246-945-088.(1) "Restricted product" means any nonprescription product containing any detectable quantity of ephedrine, pseudoephedrine, and phenylpropanolamine or their salts or isomers, or salts of isomers.(2) "Re…

(1) For the purpose of this chapter, in addition to the substances in RCW 69.43.010, a precursor substance is any of the following substances or their salts or isomers:(a) Gamma-butyrolactone (GBL); and(b) Hydriodic acid.(2) A precursor substance defined in subsection (1) of this…

(1) Any manufacturer, wholesaler, retailer, or any other person who receives from any source outside the state of Washington any precursor substance listed in WAC 246-945-065 or RCW 69.43.010 shall submit a report of such transaction within fourteen days of the receipt of that su…

(1) A permit holder who regularly transfers the same precursor substance to the same recipient may apply to the commission for authorization to submit the report of said transactions on a monthly basis. Requests for monthly reporting authorization must be received at the commissi…

(1) A manufacturer, wholesaler or distributor who sells, transfers, or furnishes a regulated product to any licensee shall report any suspicious transaction in writing to the commission.(2) For the purpose of this rule, a regulated product is defined as a product specified in RCW…

Unless exempted in RCW 69.43.110, a retailer must:(1) Verify the purchaser's identity by means of acceptable identification as defined in this chapter;(2) Ensure that the purchaser is at least eighteen years of age; and(3) Record all of the information required in WAC 246-945-078…

(1) Unless granted an exemption under RCW 69.43.110 upon the sale or attempted sale of a restricted product, each retailer shall enter and electronically transmit the following information to the methamphetamine precursor tracking system prior to completion of the transaction:(a)…

Acceptable forms of identification are defined as current foreign, federal, state, or tribal government-issued identification which include the person's photograph, name, date of birth, signature, and physical description. Acceptable forms of identification include, but are not l…

(1) The retail sales records required under WAC 246-945-078 are confidential and accessible by the commission and law enforcement agencies. Law enforcement may access the retail sales records for criminal investigations when, at a minimum, there is an articulated individualized s…

(1) Pharmacies are exempt from entering purchase information into the methamphetamine precursor tracking system when the sale of products containing ephedrine, pseudoephedrine, or phenylpropanolamine or their salts or isomers, or salts of isomers is sold pursuant to a prescriptio…

(1) The retailer must deny the sale of restricted product to purchasers who are not able to produce acceptable identification or if the sale would violate RCW 69.43.110 or federal law.(2) In the event that the retailer perceives that refusal of the purchase may place them in immi…

Pursuant to RCW 18.64.257 and 69.41.032, a medicare-approved dialysis center, a facility operating a medicare-approved home dialysis program, a manufacturer, or a wholesaler may sell, deliver, possess, or dispense directly to its home dialysis patients, in case or full shelf lots…

A medicare-approved dialysis center, a facility operating a medicare-approved home dialysis program, a manufacturer, or a wholesaler who sells, delivers, possesses, or dispenses dialysis devices and legend drugs directly to its home dialysis patients permitted by RCW 18.64.257 an…

(1) A medicare-approved dialysis center, a facility operating a medicare-approved home dialysis program, a manufacturer, or a wholesaler who sells, delivers, possesses, or dispenses dialysis devices and legend drugs directly to its home dialysis patients permitted by RCW 18.64.25…

A medicare-approved dialysis center, a facility operating a medicare-approved home dialysis program, a manufacturer, or a wholesaler who sells, delivers, possesses, or dispenses dialysis devices and legend drugs directly to its home dialysis patients permitted by RCW 18.64.257 an…

(1) All licensees of the commission must comply, at a minimum, with the following chapters of the United States Pharmacopeia (USP) when engaged in compounding nonsterile and sterile products for patient administration or distribution to a licensed practitioner for patient use or …

An individual providing pharmacy services to individuals located in Washington is required to be credentialed by the commission, unless the individual is providing pharmacy services within the scope of their employment, or affiliation, with a Washington licensed nonresident pharm…

All applications for initial licensure and renewals must be submitted on forms provided by the commission as well as any other required documentation.[Statutory Authority: RCW 18.64.005, 18.64.080, 18.130.075, 18.64.043, 18.64.044, 18.64.045, 18.64.046, 18.64.370, 18.64.460, 69.5…

(1) Unless otherwise stated, each individual shall register with the commission, as a pharmacy intern before beginning pharmacy practice experiences in Washington state. The commission shall grant a registration to practice pharmacy as a pharmacy intern to an individual who is:(a…

(1) An individual that holds a pharmacy intern registration in another U.S jurisdiction, that has registration standards substantially equivalent to Washington, may request a temporary practice permit if: (a) The applicant is not subject to denial of a credential or issuance of a…

(1) In addition to the requirements in RCW 18.64.080, an applicant for a pharmacist license who holds a baccalaureate degree in pharmacy or a doctor of pharmacy degree from a commission accredited school or college of pharmacy shall submit documentation of education and practice …

Hours reported to the commission under WAC 246-945-162, 246-945-173, and 246-945-175, shall occur as follows:(1) Hours must be completed within eighteen months from the date of graduation;(2) From a commission accredited school or college of pharmacy, U.S. jurisdiction board or c…

(1) Upon authorization by the commission or its designee, an individual applying for a pharmacist license shall take and pass a pharmacy licensure examination and jurisprudence examination approved by the commission.(2) A score of seventy-five or higher is required to pass each o…

(1) An individual who holds an active pharmacist license, in good standing, issued by another U.S. jurisdiction may apply for a pharmacist license in Washington by license transfer. In addition to the completion of the commission's application, the applicant must:(a) File for lic…

(1) A pharmacist may apply for a retired active pharmacist license status if they:(a) Hold an active pharmacist license issued by the commission under chapter 18.64 RCW that is in good standing;(b) Submit an application on a form provided by the commission; and(c) Pay the retired…

To return to active status a pharmacist with an expired license shall pay the applicable fees in accordance with WAC 246-945-990 through 246-945-992 and:(1) If the pharmacist license has been expired for less than three years the pharmacist shall meet the requirements of WAC 246-…

(1) A pharmacist may obtain an inactive license by meeting the requirements of WAC 246-12-090 and RCW 18.64.140.(2) An inactive license can be renewed in accordance with WAC 246-12-100 and by paying the applicable fees in accordance with WAC 246-945-990 through 246-945-992.(3) If…

(1) As part of the process to renew a pharmacist license, a pharmacist shall complete continuing education in compliance with this section.(2) A pharmacist shall complete the equivalent of 30 hours of continuing education each license renewal cycle. The 30 hours of continuing edu…

To receive a nuclear pharmacist endorsement, a pharmacist must:(1) Be licensed to practice in Washington;(2) Meet minimal standards of training and experience in the handling of radioactive materials in accordance with WAC 246-240-075 and submit to the commission proof of complia…

(1) To become registered as a pharmacy assistant an applicant shall submit an application to the commission that meets the requirements of WAC 246-12-020.(2) The supervising pharmacist, shall instruct the pharmacy assistant regarding their scope of practice.(3) To renew a registr…